All In Biotech

Drug Trial Radar · NCT07873229

DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine

A Phase 1, Open-Label, Fixed-Sequence, Single-Center, Two-Period, Drug-Drug Interaction Trial in Healthy Adult Participants to Evaluate the Effect of Steady-State ECC0509 on the Pharmacokinetics of Metformin (MATE1/2-K Probe Substrate), Midazolam (CYP3A4 Probe Substrate), and Caffeine (CYP1A2 Probe Substrate)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Mar 2027

Study completion Apr 2027

Sponsor

Lead sponsor
EccogeneIndustry
Sponsor type
Industry
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK) of metformin (a MATE1/2-K probe substrate), midazolam (a CYP3A4 probe substrate), and caffeine (a CYP1A2 probe substrate).

Conditions

  • Steatohepatitis, Nonalcoholic
  • Osteo Arthritis

Interventions

  • ECC0509Drug

    ECC0509 will be administered orally.

  • MetforminDrug

    Metformin will be administered orally.

  • CaffeineDrug

    Caffeine will be administered orally.

  • MidazolamDrug

    Midazolam will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
  2. Time to maximum plasma concentration of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
  3. Area under the drug concentration-time curve of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
  4. Clearance of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
  5. Maximum plasma concentration of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17
  6. Time to maximum plasma concentration of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17
  7. Area under the drug concentration-time curve of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17
  8. Clearance of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.